Attached files
| file | filename |
|---|---|
| EX-99.1 - NAVIDEA BIOPHARMACEUTICALS, INC. | v210272_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
|
Date
of Report (Date of earliest event reported)
|
February
7, 2011
|
|
NEOPROBE
CORPORATION
|
|
(Exact
name of registrant as specified in its
charter)
|
|
Delaware
|
0-26520
|
31-1080091
|
|
(State
or other jurisdiction
|
(Commission
|
(IRS
Employer
|
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
|
425
Metro Place North, Suite 300, Columbus, Ohio
|
43017
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant's
telephone number, including area code
|
(614)
793-7500
|
|
|
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02. Results of Operations and Financial Condition.
On February 7, 2011, Neoprobe
Corporation (the “Company”) issued a press release (the "Press Release")
announcing that its common stock has been cleared for listing on the NYSE
Amex. The Company's common stock, which currently trades on the OTC
Bulletin Board, will begin trading on the NYSE Amex on or about February 10,
2011. In connection with the listing, the Company’s ticker symbol
will change to “NEOP” from “OTCBB:NEOP.”
To ensure
that all the required information provided to the NYSE Amex in connection with
the Company's application had been adequately disclosed to the investing public,
the Company provided pro forma financial information in the press release to
update the financial position of the Company as reported in its most
recently completed quarterly filing with the Securities and Exchange Commission
for the nine months ended September 30, 2010. A copy of the complete text of the
Company’s February 7, 2011, press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
Statements contained or incorporated by
reference in this Current Report on Form 8-K which relate to other than strictly
historical facts, such as statements about the Company’s plans and strategies,
expectations for future financial performance, new and existing products and
technologies, anticipated clinical and regulatory pathways and markets for the
Company’s products, are forward-looking statements. The words
“believe,” “expect,” “anticipate,” “estimate,” “project,” and similar
expressions identify forward-looking statements that speak only as of the date
hereof. Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not limited
to, the Company’s continuing operating losses, uncertainty of market acceptance
of its products, reliance on third party manufacturers, accumulated deficit,
future capital needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited marketing and
manufacturing experience, risks of development of new products, regulatory risks
and other risks detailed in the Company’s most recent Annual Report on Form 10-K
and other Securities and Exchange Commission filings. The Company
undertakes no obligation to publicly update or revise any forward-looking
statements.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit
|
|
|
Number
|
Exhibit
Description
|
|
99.1
|
Neoprobe
Corporation press release dated February 7, 2011, entitled “Neoprobe
Common Stock Approved For Listing on NYSE
Amex.”
|
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
Neoprobe
Corporation
|
|||
|
Date:
February 7, 2011
|
By:
|
/s/ Brent L. Larson
|
|
|
Brent
L. Larson, Senior Vice President and
Chief
Financial Officer
|
|||
3